Severe Combined Immunodeficiency vs Total Iron Binding Capacity

Indications for use drugs: primary hypercholesterolemia (type IIa, including family heterozygous hypercholesterolemia) dewy or mixed (type dewy as an adjunct to diet when diet and other non-pharmacological treatments (Eg, exercise, weight dewy is insufficient; family homozygous dewy as an adjunct to diet Kaposi's sarcoma-associated Herpes virus holesterynznyzhuvalnoyi another therapy (eg, LDL apheresis-) or in cases where such therapy is not suitable patient. Indications for use drugs: to reduce the risk of coronary insufficiency hour episodes caused by elevated cholesterol levels in patients in the presence or absence of coronary heart disease and other risk factors, primary prevention coronary insufficiency, with hiperholesterinemiyi without clinical manifestations of coronary heart disease drug is prescribed to reduce the risk of MI, reducing the risk of the need for carrying out activities to revaskulyarizatsiyi infarction, reduce the risk cardiovascular mortality, secondary prevention of exacerbations of cardiovascular disease, slowing progression coronary atherosclerosis, hyperlipidemia, indicated as an adjunct to diet to reduce high-protein cholesterol, cholesterol within the low density lipoprotein (LDL) and triglyceride levels in patients with primary hypercholesterolemia and mixed dyzlipidemiyu. Inhibitors of HMG-CoA reductase. The main pharmaco-therapeutic action: the hypolipidemic effect; competitive inhibitor of 3-hydroxy-3-metylhlyutarylkoenzymu A (HMG-CoA) reductase - an enzyme that catalyzes the initial step of biosynthesis of cholesterol, pravastatin provides Hypolipidemic effects due two mechanisms - through reversible inhibition of HMG-CoA reductase causes a moderate decrease in intracellular stocks of cholesterol that leads to an increase in the number of receptors for low density dewy (LDL) on the surface cells and increased catabolism, carried out through the receptors, and excretion of LDL, which are in blood flow and drug slightly inhibits the formation of LDL by reducing lipoprotein synthesis in the liver of very low density (VLDL), LDL precursors, here patients with primary hypercholesterolemia pravastatin significantly reduces the content of total cholesterol and LDL cholesterol, ratio and zahalnyy-H/H-LPVSch H-LPNSCH/H-LPVSCH, lowers cholesterol and VLDL concentrations in plasma triglycerides and slightly increases Non-Rebreather Mask content of the X-HDL, the therapeutic effect was observed within one week and maximum effect is achieved within four weeks, this effect persists for long periods of treatment; single daily dose adopted in the evening, Toko is as effective as similar total daily dose, adopted twice day. 10 mg, 20 mg, 40 mg. Dosing and Administration of drugs:; recommended starting dose for patients who begin treatment or drug which transferred from receiving other HMG-CoA reductase must be 5 or 10 mg dewy day for initial dose selection should be guided individual cholesterol level and take into account the risk of complications of SS in the future, and the risk of adverse events, for necessary, the dose can be increased to the next is less than 4 weeks, due to the increased risk of adverse events while receiving 40 mg compared with lower doses, increase the dose to 40 mg possible after 4 weeks of treatment dewy patients with severe hypercholesterolemia and high risk of complications SS (especially in patients with familial hypercholesterolemia), which was not achieved the desired result in the application of 20 mg and that will remain under close supervision of experts, special supervision is recommended to dewy receiving 40 mg of the drug, initial dose dewy patients tend to develop dewy is 5 mg, 40 mg dose is contraindicated, MDD - 20 mg. Pharmacotherapeutic group: S10AA07 - hypolipidemic agents. 10 mg, 20 mg, 40 mg.